Compare Moderna, Inc. (MRNA) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? Moderna, Inc. trades at $213.49 (market cap $78.65B), while ABRDN Physical Gold Shares ETF trades at $39.87 (market cap $7.03B). The key difference: Moderna, Inc. is far larger — about 11.2× ABRDN Physical Gold Shares ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| MRNA | SGOL | |
|---|---|---|
Market Cap | $78.65B | $7.03B |
Volume | 37,373,437 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $203.46 | $51.41 |
52-Week Low | $22.36 | $37.54 |
Typical Hold Time | 59 Days | 57 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
SGOL trades at $39.81 with a 2.02% daily gain amid mixed technical signals. The overall technical picture remains bearish with moving averages indicating selling pressure, though oscillators show neutral momentum. Recent news highlights gold's sensitivity to Treasury yields and Federal Reserve policy expectations, with prices facing headwinds from rising rates but finding some support from inflation concerns and geopolitical tensions.
The outlook for SGOL is cautious with technical indicators favoring bearish momentum, while fundamental drivers depend on macroeconomic factors. Investment opportunities exist if inflation persists or geopolitical risks escalate, but risks include further rate hikes and dollar strength. Wall Street sentiment is divided with some analysts projecting declines to $4,100 while others see potential for $5,000 by mid-2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
